Retraction Note: Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture (Scientific Reports, (2017), 10.1038/s41598-017-10087-6);Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Aydin, Yucel ^b   Chedid, Milad ^a   Chava, Srinivas ^a   Danielle Williams, Donkita ^a   Liu, Shuanghu ^d   Hagedorn, Curt H ^e   Sumitran Holgersson, Suchitra ^f   Reiss, Krzysztof ^g   Moroz, Krzysztof ^a   Lu, Hua ^c   Balart, Luis A ^b   Dash, Srikanta ^a,b  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b Division of Gastroenterology   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE R; PROTEIN MDM2; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR NRF2;

CELL CULTURE; CELL LINE; CHRONIC HEPATITIS C; ENDOPLASMIC RETICULUM STRESS; GENE SILENCING; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL; METABOLISM; NUCLEOCYTOPLASMIC TRANSPORT; PATHOLOGY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS REPLICATION;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL LINE; CELLS, CULTURED; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; GENE SILENCING; GENOMIC INSTABILITY; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; NF-E2-RELATED FACTOR 2; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; REACTIVE OXYGEN SPECIES; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 85027975872     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-021-97265-9     Document Type: Erratum

References (72)

1. Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A. & Cacciapuoti, C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 22, 7824-7840, doi:10.3748/wjg. v22.i34.7824 (2016).
2. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255, doi:10.1016/S0140-6736(11)61347-0 (2012).
3. El-Serag, H. B., Kanwal, F., Davila, J. A., Kramer, J. & Richardson, P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 146, 1249-1255 e1241, doi:10.1053/j. gastro.2014.01.045 (2014).
4. Affo, S., Yu, L. X. & Schwabe, R. F. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 12, 153-186, doi:10.1146/annurev-pathol-052016-100322 (2017).
5. Trevisani, F., Frigerio, M., Santi, V., Grignaschi, A. & Bernardi, M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 42, 341-347, doi:10.1016/j.dld.2009.09.002 (2010).
6. Gaddikeri, S. et al. Hepatocellular carcinoma in the noncirrhotic liver. AJR Am J Roentgenol 203, W34-47, doi:10.2214/AJR.13.11511 (2014).
7. Panel, A. I. H. G. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62, 932-954, doi:10.1002/hep.27950 (2015).
8. Rehermann, B. HCV in 2015: Advances in hepatitis C research and treatment. Nat Rev Gastroenterol Hepatol 13, 70-72, doi:10.1038/ nrgastro.2015.227 (2016).
9. El-Serag, H. B., Kanwal, F., Richardson, P. & Kramer, J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 64, 130-137, doi:10.1002/hep.28535 (2016).
10. Reig, M. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65, 719-726, doi:10.1016/j.jhep.2016.04.008 (2016).
11. Conti, F. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65, 727-733, doi:10.1016/j.jhep.2016.06.015 (2016).
12. Cheung, M. C. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65, 741-747, doi:10.1016/j.jhep.2016.06.019 (2016).
13. Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6, 674-687, doi:10.1038/nrc1934 (2006).
14. Rusyn, I. & Lemon, S. M. Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies? Cancer Lett 345, 210-215, doi:10.1016/j.canlet.2013.06.028 (2014).
15. Bartenschlager, R., Penin, F., Lohmann, V. & Andre, P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 19, 95-103, doi:10.1016/j.tim.2010.11.005 (2011).
16. Scheel, T. K. & Rice, C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19, 837-849, doi:10.1038/nm.3248 (2013).
17. Baiceanu, A., Mesdom, P., Lagouge, M. & Foufelle, F. Endoplasmic reticulum proteostasis in hepatic steatosis. Nat Rev Endocrinol 12, 710-722, doi:10.1038/nrendo.2016.124 (2016).
18. Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 14, 581-597, doi:10.1038/nrc3800 (2014).
19. Chan, S. W. Unfolded protein response in hepatitis C virus infection. Front Microbiol 5, 233, doi:10.3389/fmicb.2014.00233 (2014).
20. Tardif, K. D., Mori, K. & Siddiqui, A. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol 76, 7453-7459 (2002).
21. Tardif, K. D., Mori, K., Kaufman, R. J. & Siddiqui, A. Hepatitis C virus suppresses the IRE1-XBP1 pathway of the unfolded protein response. J Biol Chem 279, 17158-17164, doi:10.1074/jbc.M312144200 (2004).
22. Tardif, K. D., Waris, G. & Siddiqui, A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 13, 159-163, doi:10.1016/j. tim.2005.02.004 (2005).
23. Waris, G., Turkson, J., Hassanein, T. & Siddiqui, A. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol 79, 1569-1580, doi:10.1128/JVI.79.3.1569-1580.2005 (2005).
24. Gong, G., Waris, G., Tanveer, R. & Siddiqui, A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 98, 9599-9604, doi:10.1073/pnas.171311298 (2001).
25. Joyce, M. A. et al. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog 5, e1000291, doi:10.1371/journal.ppat.1000291 (2009).
26. Sir, D. et al. Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. Hepatology 48, 1054-1061, doi:10.1002/hep.22464 (2008).
27. Ke, P. Y. & Chen, S. S. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 121, 37-56, doi:10.1172/JCI41474 (2011).
28. Shinohara, Y. et al. Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy. Biochem Biophys Res Commun 432, 326-332, doi:10.1016/j.bbrc.2013.01.103 (2013).
29. Merquiol, E. et al. HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. PLoS One 6, e24660, doi:10.1371/journal.pone.0024660 (2011).
30. Shuda, M. et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 38, 605-614 (2003).
31. Chandra, P. K. et al. HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol 184, 214-229, doi:10.1016/j. ajpath.2013.10.005 (2014).
32. Dash, S. et al. Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. Viruses 8, doi:10.3390/v8050150 (2016).
33. Chandra, P. K. et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One 9, e108616, doi:10.1371/journal.pone.0108616 (2014).
34. Chava, S. et al. Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma. Oncotarget 8, 40019-40036, doi:10.18632/oncotarget.16685 (2017).
35. Aydin, Y. et al. Interferon-alpha-induced hepatitis C virus clearance restores p53 tumor suppressor more than direct-acting antivirals. Hepatology Communications 1, 256-269, doi:10.1002/hep4.1025 (2017).
36. Ivanov, A. V. et al. Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells. PLoS One 6, e24957, doi:10.1371/journal.pone.0024957 (2011).
37. Apopa, P. L., He, X. & Ma, Q. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol 22, 63-76, doi:10.1002/jbt.20212 (2008).
38. Burdette, D., Olivarez, M. & Waris, G. Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway. J Gen Virol 91, 681-690, doi:10.1099/vir.0.014340-0 (2010).
39. Numazawa, S., Ishikawa, M., Yoshida, A., Tanaka, S. & Yoshida, T. Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol Cell Physiol 285, C334-342, doi:10.1152/ajpcell.00043.2003 (2003).
40. Reichard, J. F. & Petersen, D. R. Involvement of phosphatidylinositol 3-kinase and extracellular-regulated kinase in hepatic stellate cell antioxidant response and myofibroblastic transdifferentiation. Arch Biochem Biophys 446, 111-118, doi:10.1016/j. abb.2005.12.011 (2006).
41. Cullinan, S. B. et al. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23, 7198-7209 (2003).
42. Liu, S., Chen, R. & Hagedorn, C. H. Direct visualization of hepatitis C virus-infected Huh7.5 cells with a high titre of infectious chimeric JFH1-EGFP reporter virus in three-dimensional Matrigel cell cultures. J Gen Virol 95, 423-433, doi:10.1099/vir.0.055772-0 (2014).
43. Sdek, P. et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20, 699-708, doi:10.1016/j.molcel.2005.10.017 (2005).
44. Florczyk, U. et al. Opposite effects of HIF-1alpha and HIF-2alpha on the regulation of IL-8 expression in endothelial cells. Free Radic Biol Med 51, 1882-1892, doi:10.1016/j.freeradbiomed.2011.08.023 (2011).
45. Son, Y. O. et al. Nrf2/p62 signaling in apoptosis resistance and its role in cadmium-induced carcinogenesis. J Biol Chem 289, 28660-28675, doi:10.1074/jbc.M114.595496 (2014).
46. Shang, J. et al. Translation attenuation by PERK balances ER glycoprotein synthesis with lipid-linked oligosaccharide flux. J Cell Biol 176, 605-616, doi:10.1083/jcb.200607007 (2007).
47. Sugiura, K. et al. The unfolded protein response is activated in differentiating epidermal keratinocytes. J Invest Dermatol 129, 2126-2135, doi:10.1038/jid.2009.51 (2009).
48. Saeed, M. et al. Role of the endoplasmic reticulum-associated degradation (ERAD) pathway in degradation of hepatitis C virus envelope proteins and production of virus particles. J Biol Chem 286, 37264-37273, doi:10.1074/jbc.M111.259085 (2011).
49. McCloy, R. A. et al. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle 13, 1400-1412, doi:10.4161/cc.28401 (2014).
50. Jensen, E. C. Quantitative analysis of histological staining and fluorescence using Image. J. Anat Rec (Hoboken) 296, 378-381, doi:10.1002/ar.22641 (2013).
51. Wasserman, W. W. & Fahl, W. E. Functional antioxidant responsive elements. Proc Natl Acad Sci USA 94, 5361-5366 (1997).
52. Hernandez-Monge, J., Rousset-Roman, A. B., Medina-Medina, I. & Olivares-Illana, V. Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB. Genes Cancer 7, 278-287, doi:10.18632/genesandcancer.120 (2016).
53. Polager, S. & Ginsberg, D. p53 and E2f: partners in life and death. Nat Rev Cancer 9, 738-748, doi:10.1038/nrc2718 (2009).
54. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299, doi:10.1038/387296a0 (1997).
55. Kiffin, R., Christian, C., Knecht, E. & Cuervo, A. M. Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell 15, 4829-4840, doi:10.1091/mbc.E04-06-0477 (2004).
56. Kaushik, S. & Cuervo, A. M. Autophagy as a cell-repair mechanism: activation of chaperone-mediated autophagy during oxidative stress. Mol Aspects Med 27, 444-454, doi:10.1016/j.mam.2006.08.007 (2006).
57. Wang, Y., Singh, R., Xiang, Y. & Czaja, M. J. Macroautophagy and chaperone-mediated autophagy are required for hepatocyte resistance to oxidant stress. Hepatology 52, 266-277, doi:10.1002/hep.23645 (2010).
58. You, A. et al. Transcription factor Nrf2 maintains the basal expression of Mdm2: An implication of the regulation of p53 signaling by Nrf2. Arch Biochem Biophys 507, 356-364, doi:10.1016/j.abb.2010.12.034 (2011).
59. Davoli, T. & de Lange, T. The causes and consequences of polyploidy in normal development and cancer. Annu Rev Cell Dev Biol 27, 585-610, doi:10.1146/annurev-cellbio-092910-154234 (2011).
60. Martin, J. & Dufour, J. F. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 14, 1720-1733 (2008).
61. Wang, P. et al. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 27, 1590-1598, doi:10.1038/sj.onc.1210788 (2008).
62. Carroll, P. E. et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18, 1935-1944, doi:10.1038/sj.onc.1202515 (1999).
63. Classon, M. & Harlow, E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2, 910-917, doi:10.1038/nrc950 (2002).
64. Dick, F. A. & Rubin, S. M. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 14, 297-306, doi:10.1038/ nrm3567 (2013).
65. Vitale, I. et al. Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ 18, 1403-1413, doi:10.1038/cdd.2010.145 (2011).
66. Meng, X., Franklin, D. A., Dong, J. & Zhang, Y. MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res 74, 7161-7167, doi:10.1158/0008-5472.CAN-14-1446 (2014).
67. Menegon, S., Columbano, A. & Giordano, S. The Dual Roles of NRF2 in Cancer. Trends Mol Med 22, 578-593, doi:10.1016/j. molmed.2016.05.002 (2016).
68. Karin, M. & Dhar, D. Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis 37, 541-546, doi:10.1093/carcin/bgw060 (2016).
69. Carvajal-Yepes, M. et al. Hepatitis C virus impairs the induction of cytoprotective Nrf2 target genes by delocalization of small Maf proteins. J Biol Chem 286, 8941-8951, doi:10.1074/jbc.M110.186684 (2011).
70. Munakata, T. et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 3, 1335-1347, doi:10.1371/journal.ppat.0030139 (2007).
71. Munakata, T., Nakamura, M., Liang, Y., Li, K. & Lemon, S. M. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 102, 18159-18164, doi:10.1073/pnas.0505605102 (2005).
72. Rubin, S. M. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci 38, 12-19, doi:10.1016/j. tibs.2012.10.007 (2013).